Impact of pravastatin on secondary prevention of coronary artery disease in normolipidemic patients: five-year angiographical follow-up results of prospective randomized trial (PCS study)  by Nakagawa, Tsutomu et al.
¢, 
Q,. 
.E 
>. 
242A 
than SG, 35.4% vs 17.7% (p<0.05). These complications included myocardial infarction 
2.0/6.25, dysrrhythmia 2.0/10.4%, renal insufficiency 2.5/11.1%, ileus 2.0/18.8% infection 
0.0/6.3%, retroperitoneal bleed 2.0/2.1% and hematoma 9.8/2.1%. 
The American Surgical Association Risk Category (ASA) was equivalent in both groups. 
Mortality and discharge to a skilled nursing facility were more common in the surgical 
population (table). The mean length of stay (day) was 8.0 for surgery and 2.4 for the SG 
9roup. 
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1129-95 Ischemic ECG Response During Dipyr idamole  St ress  
Teat ing Is a Power fu l  P red ic tor  o f  Severe  Coronary  
Ar tery  Disease in Pat ients  With C laud icc t lon  Due to  
Peripheral Arter ia l  D isease 
Dennis G. Caralis. Amjad All, John T. Barron, Rush-Presbyterian-SL uke's Medical 
Center, Chicago, Illinois. 
Type of AGE ASA Aneurysm Discharged Discharged In- Expired or Direct 
treatment (years) Category size (cm) Home* Skilled care hospital Skilled hospital 
facility mortality Care* Cost ($) 
Surgery 69 111=80.0%1V=6.1+1.36 74.9% 19.1% 6.25% 25.0% 8,113 
n= 48 (42-62) 17.5% 
Stent 72 II1= 73.2%1V= 4.9 + 0.92 90.2% 9.7% 0.0% 9.8% 14,661 
Graft (52-88) 24.4% 
n=51 
*P<0.05 
Conclusion: Aortic SG appears to be associated with decreased morbidity, mortality and 
length of hospital stay. Resource utilization defined as the direct hospital cost is higher, 
but there is less utilization of skilled nursing facilities after discharge. 
1129-94 Ef fect  o f  T reatment  on Embollc Events in Patients With 
Severe Thoracic Aortic Atheromas: Interim Data 
Analysis From the NYU Atheroma Group 
Ambika C. Navar, Gregory M. Goodkin, Sunil Mirchandani, Paul A. Tunick, Itzhak 
Kronzon, NYU School of Medicine, New York, New York. 
Background: Severe aortic plaques seen on TEE are associated with a high risk of stroke 
and peripheral embolization. Previous studies have indicated a beneficial effect of war- 
farin, but only in small groups of patients. 
Methods: Since 1988, 1114 pts had thoracic aortic atheromas, at least 5mm or mobile, on 
TEE at our institution. Retrospective information regarding the occurrence of embolic 
events (stroke, TIA, or peripheral) after atheroma diagnosis by TEE, as well as treatment 
with warfarin, antiplatelet drugs (aspirin, ticlopidine, clopidogral), or statins was obtained 
from patient records or direct patient or family contact. Treatment was determined by 
referring physicians and was not randomized. Presented here are interim data from 468 
randomly selected pts. 
Results: Of the 468 pts studied, 179 (38%) received warfarin, 247 (53%) received anti- 
platalet treatment, and 165 (35%) received statin. An embolic event occurred in 97 pts 
(21%) (stroke = 48, TIA = 34, peripheral embolization = 15). Warfarin was being given to 
32 (33%) of these 97 pts, antiplatelet drugs to 48 (49%), and stafin to 18 (19%) at the 
time of their embolic events. Of the 371 pts without emboli, 147 (40%) were receiving 
warfarin, 199 (54%) antiplatelet drugs, and 147 (40%) were on statin. Many pts were on 
multiple drug regimens. The protective effect of statin with respect to embotic events was 
statistically significant (OR 0.35, 95% CI 0.2 - 0.6; P = 0.00009). No significant protective 
effect was found for warfadn (P = 0.22) or antiplatelet drugs (P = 0.45). 
Conclusions: Although these data are from an interim analysis of 42% of our pts, the 
results indicate that there may be a protective benefit of statin, and a lack of a significant 
protective effect of warfarin and antiplatelet drugs in pts with severe thoracic aortic ather- 
omas on TEE. Data from the entire cohort will be more definitive. 
1129-95 Association of Se l f -Repor ted  Le isure  Act iv i ty  and 
Coronary Risk With Carot id  Ar tery  React iv i ty  
Ronald S. McKechnie, Lori Mosca, Melvyn Rubenfira, University of Michigan, Ann Arbor, 
Michigan, Columbia Universi~ New York, New York. 
Background: Regular leisure activity has been shown to reduce cardiovascular risk and 
positively influence risk factors. Vascular reactivity, including carotid and brachial arter- 
ies, is also correlated with coronary risk. We studied the association between self- 
reported, leisure activity and carotid reactivity in response to a sympathetic stressor in 
188 adults. We also evaluated the vascular response with respect to 3 levels of coronary 
risk, Methods: Vascular reactivity was evaluated by percent and absolute change of the 
carotid artery diameter in response to a cold pressor test (CPT) and nitroglycerin. Physi- 
cal activity was assessed by a participant-racall questionnaire. Patients were stratified as 
average-risk (1 abnormal lipid level), high-risk (one coronary risk factor and >/= 1 abnor- 
mal lipid level), or CAD (coronary artery disease-prior myocardial infarction or coronary 
stenosis > 50%). Results: 67% of patients self-reported regular active, mederatsly, or 
extremely active leisure activity versus sedentary or minimally active. Of those patients, 
average-dsk patients increased their diameter in response to CPT by 4.3 +/- 2.7%, which 
was less in the high-risk group (1.4 +/- 1.5%), and vasoconstriction occurred in the CAD 
group (-2.2 +/- 1.5%) (p < 0.001 for comparisons). Among CAD patients, an active life- 
style was associated with significantly less vasoconstriction compared to less active 
patients (-2,2 +/- 1.5% vs. -3.5 +/- 1.6%, p < 0.05). After adjusting for age, BMI, HDL-cho- 
lesterol, triglycerides, baseline diameter and systolic blood pressure, linear regression of 
carotid reactivity in response to CPT in the CAD group maintained the significant associ- 
ation between leisure activity and carotid reactivity (Model R2=0.38, p < 0.05). Conclu- 
sion: In patients self-reporting active levels of leisure activity, this study suggests an 
inverse response of carotid reactivity to CPT in the presence of more coronary risk fac- 
tors, with a significant benefit of leisure activity in patients with CAD. This supports 
national recommendations that regular leisure activity may reduce cardiovascular risk 
potentially through improved endothelial function, specifically in patients with CAD. 
The significance of ST-segment depression in patients undergoing exercise stress test- 
ing has been well investigated; the significance of new ischemic ST depression during 
dipyridamole stress testing has not. This was a cross-sectional observational study of 
100 consecutive men or women (mean age 65 ± 14 years) with intermittent claudication 
of the lower extremities due to peripheral artedal disease (PAD) as indicated by Ankle 
Brachial Index (ABI) <0.8, who also demonstrated new (compared to baseline) ischemic 
ST-segment depression following intravenous dipyridamole infusion (horizontal or 
downsloping ST-segment depression of at least 0.1 mv at 80 ms from the J point on the 
ECG). Dipyridamole was infused using a standard protocol (0.14 mg/kg infused over 4 
min). All patients (100%) had abnormal single photon emission computed tomagraphic 
(SPECT) images consistent with ischemia. Of the 100 patients, 92 agreed to undergo 
coronary angiography. Coronary angiography revealed that all patients had significant 
left main and/or multivessel coronary artery disease (at least 75% luminal stenosis). 
Thus, the appearance of new ST-segment depression during dipyridamole infusion is a 
powerful predictor of severe coronary artery disease in patients with claudication due to 
PAD. 
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1130-73 S imvastat in  P lus  N iac in  Protect  Against 
Atheroac le ros l s  Progression and Clinical Events in 
Coronary Artery  Disease Pat ients  With Metabo l i c  
Syndrome 
Xue-Qiao Zhao, Josh Morse, Atan Chad, Lloyd Fisher, Alice Dowdy, John J. Albers, Jid 
Frohlich, B. Greg Brown, University of Washington, Seattle, Washington, University of 
British Columbia, Vancouver, British Columbia, Canada. 
Background: Effects of simvastatin plus niacin (SN(+)) on lipide, coronary atherosclerosis 
progression and clinical events in patients (pts) with metabolic syndrome (MSyn) were 
evaluated in the NIH-funded, a double-blinded, placebo-controlled, HDL Atherosclerosis 
Treatment Study (HATS). Method: Of 160 CAD pts enrolled and randomized to treatment 
(Rx) with SN(+) (daily dose 2-4 grn+10-20 rag) or placebo (SN(-)) in HATS, 77 (48%) had 
Msyn, which was defined as having any 3 of the following 4 criteria: (1) tdglycerides >=50 
mg/dl; (2) HDLc <40 in men or <50 in women; (3) treated hypertension or blood pressure 
>=130/85 mmHg; and (4) fasting glucose >=110 mg/dl, The lipid responses to Rx, pri- 
mary QCA endpoint (mean change in % stenosis) and clinical endpoint (CAD death, MI, 
stroke, or revascularization) were compared between SN(+) and SN(-) in both pts with 
and without MSyn. Results: See table. *: vs baseline p<0.001, 1": vs SN(-), p<O.05. ~:: vs 
MSyn(-) p=0.02. Conclusions: Patients with MSyn have a significantly greater rate of 
CAD progression and a 2-fold higher frequency of clinical events than without, Treatment 
with SN effectively lowers total cholesterol, tdglycerides and LDLc, raises HDLc without 
significantly affecting fasting glucose and insulin levets, and reduces CAD progression by 
90% and cardiovascular events by 40% in patients with MSyn. These data suggest that 
patients with MSyn should be treated more aggressively and simvastatin plus niacin 
appear to be an effective thera W, 
N Total LDLc Tdglycaddss HDLc Glucose InsulinQCA %S Event n (% 
cholesterol Base/Rx Base/Rx Base/Base/Rx Base/ change of pts) 
Base/Rx Rx Rx (SD) 
SN(+)MSyn(+)32 203/148" 125/76" 251/176" 31/39" 115/118 30/37 0.4 6/34(18%) 
(4.0)? 
MSyn(-)41 195/138" 126/78" 206/128" 31/36" 97/106 23/27 0.1 1/46(2%)? 
(2.2)? 
SN(-) MSyn(+)37 197/192 116/109 258/271 32/33 109/109 24/26 4.1 13/43(30%) 
(5.9)$ 
MSyn(-) 36 191/187 130/121 153/165 32/34 92/100 20/24 1.4(2.9) 5/37(14%) 
1130-75 Impact  o f  P ravsetat in  on  Secondary  P revent ion  o f  
Coronary  Ar tery  Disease in Normol lp ldemlc  Pat ients:  
Five-Year Angiogrephical Follow-Up Results of 
Prospective Randomized Trial (PCS study) 
Tsutomu Nakaoawa. Tohru Kobeyeshi, Nobuhisa Awata, Johan H. Reiber, Shinichi Sato, 
Tomoko Kobayashi, ¥oshihiro Takeda, Osaka Medical Canter for Cancer and 
Cardiovascular Diseases, Osaka, Japan, Department of Radiology, Leiden University 
Medical Center, Leiden, The Netherlands. 
Background: Prevention of Coronary Sclerosis (PCS) Study was designed to evaluate 
the long-term angiographic effect of pravastatin on secondary prevention of progression 
of coronary artery disease (CAD). Methods: 329 patients with CAD were enroUed and 
classified into three groups due to serum total cholesterol level: Group1 (TC>=220 rag/ 
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dl), Group2 (220>TC>=180), Greup3 (TC<180). Normocholesterolemic patients (G2) 
were randomized to two subgroups 2a and 2b. 10mg of pravastatin was given to the 
patients in G1 and G2a. CAG was performed at baseline(BL), follow-up of 2 and 5 years. 
Coronary artedograms were analyzed by QCA at the Core Laboratory. Intervention or 
CABG related coronary branches were excluded from analysis• Primary endpoint was 
angiographic coronary progression evaluated by mean segment diameter (MSD) and 
minimum obstruction diameter (MOD). Secondary sndpoints were clinical events• 
Results: 188 patients had at least one coronary branch to be evaluated. 1021 segments 
for MSD and 849 segments for MOD were analyzed by QCA (data are shown in the 
table: * p<0.05, ** p<0.01 vs. G2b). Both changes in MSD and MOD in G2a were signifi- 
cantly less than those in G2b. Cardiac events (AMI, cardiac death, PTCA and CABG) 
were 31.3% in G1, 24•1% in G2a, 28.8% in G2b and 20.0% in G3. Conclusion: Five- 
years angiographic study revealed cholesterol-lowering therapy by pravastatin prevented 
progression of coronary atheroscleresis even in normolipidsmic patients with CAD. 
Five-Year Follow-Up QCA Results 
Group TC(mg/dl) MSD MOD 
n BL 5y F/U Change n BL 5y F/U Change 
G1 >=220 505 2.630 2.592 -0.037 434 2.029 1.955 -0.074 
G2a 180-219 199 2.715 2~690 -0.025* 158 2.128 2.091 -0.036** 
G2b 180-219 205 2.679 2.610 -0,069 178 2.090 1.934 -0.156 
G3 <=179 112 2.683 2.627 -0,055 79 2.068 2.015 -0.053 
1130-76 Ef fects  of Lipid-lowering Therapy With AtorvastaUn on 
Endothelial Function and Aortic Pulse Wave Velocity in 
Patients With Hypercholesterolemia 
Hideki Watanabe. Masaaki Kakihana, Kunio Nakagawa, KINU Medical Association 
Hospital, Mitsukaido, Japan,/baraki Prefectural University of Health Sciences, Ami, 
Japan• 
To evaluate effects of atorvastatin and vitamin E on endothelial function and aortic stiff- 
ness, thirty-six patients with untreated hypereholastarolemia (total cholesterol>220 mg/ 
dL) were randomized to receive atorvastatin (10mg/day, A group, n=12), vitamin E 
(6001U/day, E group, n=12) or placebo (P group, n=12). By using ultrasound system with 
a 7.5-MHz transducer, the brachial artery diameter was measured at rest and during 
reactive hyperemia, and then before and after 0.3 mg of sublingual nitroglycerin (NTG). 
We measured plasma TBARS (thiobarbitudc acid reactive substances) to evaluate oxi- 
dative stress, and also measured aortic PWV (pulse wave velocity) by using a non-inva- 
sive technique to evaluate aortic stiffness• Measurements were performed at baseline 
and at 4 and 8 weeks after the treatments. At baseline, there was no difference in lipid 
parameters, TBARS (nmot/mL), flow-mediated dilatation (FMD, %increase in diameter 
during hyperemia), NTG-induced dilatation (NID, %increase in diameter after NTG), and 
PWV among three groups. Total cholesterol level was decreased in the A group (4 
weeks: -19%; 8 weeks: -26%), and TBARS was decreased in the E group after 4 and 8 
weeks (Baseline: 2.4±0.7, 4 weeks: 1.9±0.6, 8 weeks: 1.6±0.6). FMD was increased in 
the A and E groups after 4 and 8 weeks. PWV was decreased in the A group after 8 
weeks• NID did not change during the study• Conclusion: Lipid-lowering therapy with 
atorvastatin restores endothelial function and PWV in patients with hypercholester- 
olemia. 
Baseline 4 weeks 8 weeks 
FMD Aton, astatin 3.2 • 1 .O 7.9 • 2_0~1" 9.3 • 1 .~el" 
(%) Vitamin E 3.2 • 0.8 5.2 • 1 .Tt 5.3 • 1 _7t 
Placebo 3.2 • 0.6 3.3 • 1.2 3A • 1.2 
NID Aton, astatin 18.3 • 1.5 17.8 • 2.4 17 .9 ,  1.3 
(~:) YitaminE 17 .7 ,1 .5  17 .9 ,1 :3  18 .0 ,1 .4  
Placebo 18 .5 ,1_4  18 .0 ,1_6  18 .4 ,2_3  
PWV Atorvastatin 1803,116  1738 • 117 1427 ± gs~t 
(cmlsec) Vitamin E 1836 • 118 1823 • 115 175g,  104 
Placebo 1815 • 118 1810 • 138 1806,125  
Mean , SD, w'p<O.Ol vs vitamin E, 1"p<0.01 vs placebo 
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1131-77 The Prognostic Value of Ambulatory Blood Pressure in 
Treated Hypertension: The Office Versus Ambulatory 
(OVA) Blood Pressure Study 
Denis L. Clement, Marc De Buvzere, Dirk De Bacquer, Peter De Leeuw, Daniel A. 
Dupraz, Robert Fagard, Peter Gheeraert, Eoin O'Brien, for the OvA Investigators, 
University Hospital, Ghent, Belgium. 
Background. Prognostic value of ambulatory blood pressure recordings (ABP) in arterial 
hypertension has been studied in several large-scale event-based cohort studies mostly 
with ABP recordings made in untreated or placebo-treated subjects. The Office versus 
Ambulatory (OVA) European multicentre BP study examined whether ABP predicts car- 
diovascular (CV) events and mortality over and above office blood pressure (OBP) in 
treated hypertensive patients ( ABP recordings at > 3 months treatment). Methods. We 
followed 1963 eligible patients (median follow-up 5 years)• There were 157 patients with 
a well-documented validated first new CV event since enrolment. Total mortality com- 
prised 78 cases• Results. Cases (n = 157) were older, had higher total cholesterol and 
triglycerides, had more diabetes and more previous CV history and comprised more 
men. Office and ambulatory (24-h, day- and night-time) systolic BP were higher in the 
cases. In Cox proportional hazards models adjusted for age, gender, risk factors, previ- 
ous CV history and office BP systolic ABP still had independent significant predictive 
value over and above systolic OBP, while significance for diastolic ABP was not reached: 
systolic 24-h ABP 1.4711.24-1.74], systolic clay-time ABP 1.3911.18-1.65], systolic night- 
time ABP 1.4511.24-1.70] ( hazard ratio for 1 SD BP increase, [95%CI]). Even in 
patients(25%) with systolic OBP < 140 mmHg, subjects with high systolic ABP (particu- 
larly at night) had a higher incidence of all CV events. Further subanalysis largely con- 
firmed our results for CV mortality (n = 38). However in adjusted Cox proportional 
hazards models neither systolic or diastolic ABP could predict total mortality ( n = 78) 
over and above OBP. Conclusion. The OvA study demonstrated that systolic ABP pre- 
dicts CV events over and above systolic OBP; this is not the case for diastolic ABP. ABP 
was not predicting total mortality over and above OBP. The OvA study gives evidence 
that ABP monitoring improves CV risk stratification in treated hypertensive patients• 
1131-78 Patient Knowledge and Awareness of the Importance of 
Elevated Systolic Blood Pressure 
Susan A. Oliveria. Roland S. Chen, Bruce D. McCarthy, Catherine C. Davis, Martha N. 
Hill, Wei/I Medical College of Come//University, New York, New York, Bristol-Myers 
Squibb Pharrnaceutica/ Research Institute, Plainsboro, New Jersey. 
Background; improved recognition of the importance of systolic blood pressure (SBP) 
has been identified as one of the major public health challenges in the prevention and 
treatment of hypertension (HTN). This study assesses HTN knowledge and awareness in 
a hypertensive population, specifically focusing on SBP. 
Methods: We identified patients with HTN (n=2,264) in the pdmary care setting of a large 
Midwestern health system using automated claims data (ICD-9 codes 401.0 through 
401.9). We randomly selected 1,150 patients and report interim results on the initial 683 
completed patient telephone interviews (59% response rate); data collection is ongoing. 
Results: In this population of hypertensive patients, awareness was high, with 90% 
reporting that a healthcare provider had told them that they have HTN or high blood pres- 
sure (HBP); however, 39% of patients did not know their blood pressure (BP) level. Of 
patients who did know their BP, 54% reported levels that were _>140 mm Hg and/or _>90 
mm Hg for SBP and diastolic blood pressure (DBP), respectively• Thirty-seven percent of 
these patients reported elevated systolic levels only (SBP _>140 mm Hg and DBP <90 
mm Hg). Interestingly, only 25% of patients with elevated SBP and/or DBP perceived that 
their BP was high• Eighty-two percent of all patients correctly identified the meaning of 
HTN as "high blood pressure." Thirty-two percent of patients correctly identified SBP as 
the "top" number of their reading; 29% correctly identified DBP as the "bottom" number; 
and, overall, only 27% of the patients were able to correctly identify both systolic and 
diastolic BP measures• Twenty-six percent and 24% did not know the optimal level for 
SBP and DBP, respectively. When asked whether the DBP or SBP level was more impor- 
tant in the control and prevention of disease, 43% reported DBP, 14% reported SBP, 28% 
reported that both were important, and 14% did not know. 
Conclusions: These results suggest that although awareness of HTN is high, patients 
do not understand the importance of elevated SBP levels nor the current status of their 
BP control• An opportunity exists to focus patient education programs and interventions 
on the cardiovascular risk associated with elevated SBP levels• 
1131-79 A Compar i son  of  Pressure and Time Characteristics 
Between Aortic and Radial Blood Pressure Waveforms 
Sarah A. Hoee, lan "1. Meredith, James D. Cameron, Monash Medical Centre, Monash 
University, Me/bourne, Australia, La Trobe Universi~ Me/bourne, Australia• 
Background. It is well known that the shape of blood pressure waveforms varies over the 
arterial system• Differences in pressure wave shape and associated descdptive parame- 
ters between brachio-r'edial nd proximal aortic sites are of interest due to suggestions that 
central blood pressure may be a more appropriate clinical indicator than traditional blood 
pressure assessment. 
Methods. Simultaneous invasive ascending aortic (6 or 7Fr coronary catheter) and radial 
artery (applanation tonometry, Millar~ Mikro-tip~ catheter pressure transducer) pressure 
waveforms were recorded using Chart for Powertab, sampling at 200Hz in 98 subjects 
(76male:22female) undergoing elective coronary procedures• Radial waveforms were 
scaled to aortic mean and diastolic pressures by linear interpolation• Parameters for com- 
parison included systolic blood pressure (SBP), augmentation index (AI), diastolic lad) and 
systolic (As) pressure integrals and times to peak pressure (Tp) and to dichrotic notch (Ts). 
Results. Results are expressed comparing radial with aortic sites. Scaled radial SBP was 
closely and linearly related to measured aortic SBP (y=0.9098x + 24.22; p<0.001, r2=0.77) 
with an average difference over the physiological BP range of 12mmHg. Ad and As mea- 
sured at the two sites were also closely associated (r2=0.93 and 0.84raspectively; both 
p<0.00t), as were Tp and Ts (r2=0.2, 0.6; both p<0.001). Although achieving conventional 
significance the association between radial and aortic AI was, as expected, weak (=2--0.04, 
p<0.05). Regression slopes for SBP, Ts, Ad and As did not differ significantly from 1. 
Conclusions• Despite substantial differences in shape between radial and aortic BP wave- 
forms, with close linear relationships and regression slopes of 1, many time, pressure and 
pressure time integral parameters of the central aortic pressure waveform may be deduced 
simply from peripheral waveform data without the need for complex transformation of data• 
Our data suggest that blood pressure ranking, and cardiovascular isk, will be unchanged 
based on either central or peripheral SBP and thus derivation of central aortic waveforms 
may not improve upon conventionally available blood pressure data. 
